2 Pharma Stocks Buzzing in the Options Pits After Earnings

Group 1: AbbVie Inc (NYSE:ABBV) - AbbVie reported adjusted first-quarter earnings of $2.46 per share on$13.3 billion in revenue, exceeding analyst expectations [2] - The company raised its full-year outlook, projecting $16.5 billion in sales for its psoriasis drug Skyrizi [2] - AbbVie shares are up 1.1$182.53, and are now 10% higher over the last 12 months despite a 12% pullback this quarter [2][3] Group 2: Options Activity for AbbVie - Over 9,000 call options for AbbVie have been traded, which is quadruple the average intraday volume [4] - The most popular option is the weekly 4/25 190-strike call, with new positions being opened at the weekly 5/2 200-strike call [4] Group 3: Gilead Sciences Inc (NASDAQ:GILD) - Gilead's first-quarter revenue of $6.7 billion fell short of the forecasted$6.8 billion, leading to a 3.9% drop in share price to $102.45 [5] - RBC and Morgan Stanley raised their price targets to$92 and $135, while Oppenheimer lowered its target from$132 to $125 [5] - Gilead shares are 11$119.96 [6] Group 4: Options Activity for Gilead - Gilead call options are trading at five times the average intraday volume, with notable sell-to-open activity in the weekly 5/2 109-strike call [6] - The weekly 4/25 108-strike call is also seeing significant activity, expiring at the close today [6]